NANOFLUIDETEC: Rapid and automatable detection for SARS-Cov-2 based on PCR, nanotechnology and microfluidics (IN852D 2021/5).
Companies: AMSlab, AMSbiopharma, Bflow and Campus de Lugo de la Universidad de Santiago de Compostela
Project: Rapid and automatable detection for SARS-Cov-2 based on PCR, nanotechnology and microfluidics.
Objective: The overall objective of this project is to develop a point-of-care system for the detection of SARS-CoV-2 based on molecular techniques and integrating nanotechnology and microfluidics with automation and potential connectivity for communication.
The consortium that will carry out this project is formed by 3 Galician SMEs: AMSlab (project leader), AMSbiopharma, BFlow and the Lugo Campus of the University of Santiago de Compostela through the Single Molecule Fluorescence research unit, which will collaborate jointly for its execution.
Thus, NANOFLUIDETEC will make use of the incorporation of essential enabling technologies (EETs) in the research and development of new products with high added value that allow exploring new markets based on the integration of science and technology, especially in the areas of genetics, nanotechnology, microelectronics, photonics, biotechnology, advanced manufacturing and processing, and their treatment and operability through information and communication technologies (ICT).
Total budget: 258.751,04 €
This project is subsidized by the Galician Agency for Innovation (GAIN), financed by ERDF funds and supported by the Xunta de Galicia through the second vice-presidency and Consellería de Economía, Empresa e Innovación. The operation is funded through the CONECTA COVID 2021 program under the REACT-EU axis of the Feder Galicia 2014-2020 operational program, as part of the European Union’s response to the COVID-19 pandemic.